Referred to the House Committee on Energy and Commerce.
This bill amends Title XIX of the Social Security Act to require the Medicaid program to cover lung cancer biomarker testing. It inserts “lung cancer biomarker testing” into the list of services that must be covered under section 1905(a) and requires coverage under section 1937(b)(5) (applicable to benchmark/alternative benefit plans).
Scope and definition of “lung cancer biomarker testing” — liberals want broad access tied to equity; conservatives want narrow, evidence-limited definitions.
Relative to its intended legislative type, this bill is a narrowly targeted substantive statutory amendment that explicitly adds lung cancer biomarker testing to the list of Medicaid-covered items and establishes an effective date, but it provides minimal operational, fiscal, definitional, or oversight detail beyond the statutory insertion.
This bill amends Title XIX of the Social Security Act to require the Medicaid program to cover lung cancer biomarker testing.
It inserts “lung cancer biomarker testing” into the list of services that must be covered under section 1905(a) and requires coverage under section 1937(b)(5) (applicable to benchmark/alternative benefit plans).
The coverage mandate takes effect January 1, 2027.
As a narrow, technocratic expansion of a clinical covered service, the bill has attributes that help it attract support across the aisle. Its odds are limited by potential fiscal concerns (no offsets in the text), the imposition of a federal requirement on state Medicaid programs, and Senate procedural hurdles. Inclusion in a larger legislative package or a favorable cost estimate would materially raise its prospects.
Relative to its intended legislative type, this bill is a narrowly targeted substantive statutory amendment that explicitly adds lung cancer biomarker testing to the list of Medicaid-covered items and establishes an effective date, but it provides minimal operational, fiscal, definitional, or oversight detail beyond the statutory insertion.
Scope and definition of “lung cancer biomarker testing” — liberals want broad access tied to equity; conservatives want narrow, evidence-limited definitions.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and definition of “lung cancer biomarker testing” — liberals want broad access tied to equity; conservatives want narrow, evidence-limited definitions.
A mainstream liberal would view this bill favorably as an expansion of access to precision medicine for low-income and disabled people on Medicaid.
They would see it as a targeted health equity measure that helps ensure Medicaid enrollees can receive guideline-recommended molecular testing that can guide targeted cancer treatments.
They would want to ensure the policy is implemented in a way that actually improves outcomes and does not create barriers such as narrow definitions or onerous prior authorization.
A moderate would generally support the goal of expanding medically indicated testing to Medicaid beneficiaries but would be attentive to cost, federal-state balance, and clarity in implementation.
They would favor evidence-based limits and CMS guidance to prevent inconsistent application across states and to control unnecessary spending.
They would want clear definitions and administrative processes that minimize burden on states and providers.
A mainstream conservative would be skeptical of a federal mandate that expands required Medicaid benefits, emphasizing state flexibility, fiscal prudence, and concerns about expanding federal obligations.
They would worry about new costs for state Medicaid programs and potential overreach by requiring coverage of a specific medical service.
They might be open to limited, evidence-based coverage but prefer mechanisms that preserve state discretion or tie mandates to demonstrated clinical benefit.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
As a narrow, technocratic expansion of a clinical covered service, the bill has attributes that help it attract support across the aisle. Its odds are limited by potential fiscal concerns (no offsets in the text), the imposition of a federal requirement on state Medicaid programs, and Senate procedural hurdles. Inclusion in a larger legislative package or a favorable cost estimate would materially raise its prospects.
The bill has not accumulated any surfaced votes yet.
Scope and definition of “lung cancer biomarker testing” — liberals want broad access tied to equity; conservatives want narrow, evidence-li…
As a narrow, technocratic expansion of a clinical covered service, the bill has attributes that help it attract support across the aisle. I…
Relative to its intended legislative type, this bill is a narrowly targeted substantive statutory amendment that explicitly adds lung cancer biomarker testing to the list of Medicaid-covered items and establishes an eff…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.